Effects of Obex in Overweight and Obese Subjects With or Without Impaired Fasting Glucose: A Pilot Study.
Obex is a dietary supplement to help weight loss. The purpose of this study was to evaluate the effect of Obex in overweight/obese participants with or without impaired fasting glucose. This was an open-label pilot study conducted with 40 overweight and obese subjects, 23–60 years old with a body ma...
| Publicado en: | Journal of Dietary Supplements Vol. 14; no. 6; pp. 626 - 640 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Taylor & Francis Ltd
2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=122856993&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 122856993 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 19390211 2Y62 jtl: Journal of Dietary Supplements issn: 19390211 maglogo: N pubinfo: dt: 2017 vid: 14 iid: 6 pid: 377 pub: Taylor & Francis Ltd place: Philadelphia, Pennsylvania artinfo: ui: 122856993 122856993 122856993 10.1080/19390211.2017.1304482 122856993 ppf: 626 ppct: 14 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Effects of Obex in Overweight and Obese Subjects With or Without Impaired Fasting Glucose: A Pilot Study. aug: au: Cabrera-Rode, Eduardo Rodríguez, Janet Álvarez, Aimee Echevarría, Ragmila Reyes, Antonio Darwin Cubas-Dueñas, Ileana Turcios-Tristá, Silvia Elena Díaz-Díaz, Oscar affil: Department of Immunology, National Institute of Endocrinology, Havana, Cuba sug: subj: Dietary Supplements Weight Loss Obesity Pilot Studies Human Insulin Resistance Blood Glucose Monitoring Glucose Tolerance Test ab: Obex is a dietary supplement to help weight loss. The purpose of this study was to evaluate the effect of Obex in overweight/obese participants with or without impaired fasting glucose. This was an open-label pilot study conducted with 40 overweight and obese subjects, 23–60 years old with a body mass index of 25–44 kg/m2(20 participants with impaired fasting glucose [IFG] and 20 with normal glucose levels). Participants received Obex at a dose of one sachet before the two main meals of each day for 3 months. In addition to anthropometric measures and blood pressure (BP), fasting plasma glucose, lipid profile, insulin, creatinine, and uric acid were determined. Insulin resistance (HOMA-IR) and beta-cell function (HOMA-B) were assessed. Three indirect indices were used to calculate insulin sensitivity. Compared to baseline, Obex significantly reduced body weight, body mass index, waist circumference, waist/hip ratio, and waist/height ratio in both groups of participants (p<.05). In individuals without IFG, Obex improved HDL-c (high-density lipoprotein cholesterol) (p<.0001) and lowered BP (p<.05). After 3 months of Obex, subjects with IFG showed a reduction in fasting glucose concentrations (p<.0001). Compared to baseline, this group also showed improved insulin sensitivity and HDL-c (p<.05). In conclusion, the consumption of Obex contributed to weight reduction, improved glucose tolerance and insulin sensitivity, as well as HDL-c, and appears to be safe in overweight/obese adults with impaired fasting glucose. Obex may be beneficial for weight loss, indicating that further studies are required. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|